Enavatuzumab

Enavatuzumab is a humanized monoclonal antibody used in the treatment of solid tumors. It targets the TWEAK receptor.^[1]

Enavatuzumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	TWEAK receptor
Clinical data
ATC code	none
Identifiers
CAS Number	1062149-33-0 N
ChemSpider	none
UNII	914910XFBB
KEGG	D09896
Chemical and physical data
Formula	C6334H9792N1700O2000S42
Molar mass	143104.43 g·mol−1
NY (what is this?)  (verify)

Enavatuzumab was developed by Facet Biotech Corp.^[2]